Proto Labs Sees Q3 Revenue Jump, Net Income Flat Amid Rising Costs

TL;DR

PRLB's Q3 revenue growth is a good sign, but flat net income and rising costs mean they're running harder just to stay in place.

AI Summary

Proto Labs Inc. reported a revenue increase of 7.76% to $135.366 million for the three months ended September 30, 2025, up from $125.619 million in the same period of 2024. Net income also saw a slight increase, reaching $7.216 million in Q3 2025 compared to $7.189 million in Q3 2024. For the nine months ended September 30, 2025, revenue grew to $396.634 million from $379.140 million, a 4.61% increase, while net income decreased to $15.242 million from $16.997 million, a 10.32% decline. The company's cash and cash equivalents increased to $104.422 million as of September 30, 2025, from $89.071 million at December 31, 2024. Total assets rose to $756.855 million from $743.512 million over the same period. Share repurchases continued, with $36.732 million spent in the nine months ended September 30, 2025, reducing outstanding shares to 23,677,746 from 24,226,088 at December 31, 2024. Operating expenses increased to $52.483 million in Q3 2025 from $48.650 million in Q3 2024, driven by higher marketing and sales, R&D, and general and administrative costs.

Why It Matters

For investors, Proto Labs' Q3 2025 revenue growth of 7.76% is a positive signal, indicating continued demand for its rapid manufacturing services. However, the flat net income despite revenue gains, coupled with a 10.32% decline in net income year-to-date, suggests margin pressures and increased operating expenses, which could impact profitability and shareholder returns. The ongoing share repurchases, totaling $36.732 million in the first nine months of 2025, demonstrate a commitment to returning capital to shareholders and can support EPS, but also reduce cash available for other investments. In a competitive landscape for on-demand manufacturing, Proto Labs' ability to manage costs while expanding its market presence will be crucial for long-term value creation for investors and job security for employees.

Risk Assessment

Risk Level: medium — While revenue increased by 7.76% in Q3 2025, net income remained nearly flat at $7.216 million, indicating potential margin compression. Furthermore, the nine-month net income decreased by 10.32% from $16.997 million in 2024 to $15.242 million in 2025, despite a 4.61% revenue increase, suggesting a challenge in translating top-line growth into bottom-line profit.

Analyst Insight

Investors should monitor Proto Labs' upcoming earnings calls for detailed explanations on cost management strategies and future profitability outlook. Given the flat Q3 net income and year-to-date decline, a 'hold' position is advisable until there's clearer evidence of improved operating leverage or a reversal in the net income trend.

Financial Highlights

debt To Equity

0.14

revenue

$135.366M

operating Margin

6.51%

total Assets

$756.855M

total Debt

$13.149M

net Income

$7.216M

eps

$0.30

gross Margin

45.28%

cash Position

$104.422M

revenue Growth

+7.76%

Revenue Breakdown

Key Numbers

• $135.366M — Q3 2025 Revenue (Increased from $125.619M in Q3 2024, a 7.76% rise.)
• $7.216M — Q3 2025 Net Income (Slightly up from $7.189M in Q3 2024, indicating flat profitability.)
• $396.634M — YTD 2025 Revenue (Increased from $379.140M in YTD 2024, a 4.61% growth.)
• $15.242M — YTD 2025 Net Income (Decreased from $16.997M in YTD 2024, a 10.32% decline.)
• $104.422M — Cash and Cash Equivalents (Increased from $89.071M at December 31, 2024, showing improved liquidity.)
• $756.855M — Total Assets (Increased from $743.512M at December 31, 2024.)
• $36.732M — Common Stock Repurchases (Amount spent in the nine months ended September 30, 2025, reducing outstanding shares.)
• 23,677,746 — Shares Outstanding (As of September 30, 2025, down from 24,226,088 at December 31, 2024.)
• $52.483M — Q3 2025 Total Operating Expenses (Increased from $48.650M in Q3 2024, contributing to flat net income.)
• $0.30 — Q3 2025 Diluted EPS (Consistent with $0.29 in Q3 2024, despite share repurchases.)

Key Players & Entities

• Proto Labs Inc. (company) — Registrant for the 10-Q filing
• SEC (regulator) — Securities and Exchange Commission
• $135.366 million (dollar_amount) — Revenue for Q3 2025
• $125.619 million (dollar_amount) — Revenue for Q3 2024
• $7.216 million (dollar_amount) — Net income for Q3 2025
• $7.189 million (dollar_amount) — Net income for Q3 2024
• $396.634 million (dollar_amount) — Revenue for nine months ended September 30, 2025
• $15.242 million (dollar_amount) — Net income for nine months ended September 30, 2025
• $104.422 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $36.732 million (dollar_amount) — Repurchases of common stock for nine months ended September 30, 2025

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for raw materials and manufacturing components. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact production capacity and lead times, potentially affecting revenue and customer satisfaction.
• Intense Competition [medium — market]: The additive manufacturing and rapid prototyping market is highly competitive, with numerous players offering similar services. Proto Labs faces pressure from both established competitors and emerging companies, which could lead to pricing pressures and market share erosion.
• Data Security and Privacy [medium — regulatory]: As a digital manufacturing service, Proto Labs handles sensitive customer design data. Breaches in data security or non-compliance with privacy regulations (e.g., GDPR, CCPA) could result in significant financial penalties, reputational damage, and loss of customer trust.
• Economic Downturn Impact [medium — financial]: The company's revenue is sensitive to broader economic conditions. A significant economic slowdown or recession could lead to reduced demand for prototyping and manufacturing services from its customers, impacting revenue and profitability.
• Technological Obsolescence [low — operational]: The rapid pace of technological advancement in manufacturing could render Proto Labs' current equipment and processes obsolete. Failure to invest in and adopt new technologies could lead to a competitive disadvantage.

Industry Context

Proto Labs operates in the rapidly evolving digital manufacturing and 3D printing industry. This sector is characterized by intense competition, rapid technological advancements, and a growing demand for on-demand, customized production. Key trends include the increasing adoption of additive manufacturing for both prototyping and end-use parts, and the integration of digital workflows from design to production.

Regulatory Implications

Proto Labs must navigate regulations related to data privacy and security, given the sensitive nature of customer design files. Compliance with international data protection laws (like GDPR) is crucial. Additionally, as a manufacturer, adherence to product safety and environmental regulations in the regions it operates is necessary.

What Investors Should Do

1. Monitor operating expense growth relative to revenue.
2. Evaluate the sustainability of revenue growth.
3. Assess the impact of share repurchases on EPS and shareholder value.
4. Analyze the decline in year-to-date net income.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $135.366M in revenue, a 7.76% increase year-over-year, and $7.216M in net income.
• 2025-09-30: Balance Sheet Date — Company held $104.422M in cash and cash equivalents, an increase from year-end 2024.
• 2025-09-30: Shares Outstanding Update — Outstanding shares reduced to 23,677,746 due to ongoing share repurchase program.
• 2024-12-31: End of Fiscal Year 2024 — Company had $89.071M in cash and cash equivalents and 24,226,088 shares outstanding.

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair market value of its net identifiable assets. (Represents a significant portion of Proto Labs' assets ($273.991M), indicating past acquisitions.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. (Represents $450.852M of the company's equity, reflecting historical stock issuance.)

Retained earnings

The cumulative amount of net income that a company has kept over time, rather than distributing to shareholders as dividends. (At $238.568M, it shows the company's historical profitability and reinvestment strategy.)

Accumulated other comprehensive loss

Unrealized gains and losses that are not included in net income but are reported in a separate section of the income statement. (A negative balance of ($24.724M) indicates unrealized losses, potentially from foreign currency translation or investment fluctuations.)

Operating lease assets

Assets recognized on the balance sheet for the right to use an underlying asset for a lease term. (Represents $2.015M in assets related to leased properties or equipment.)

Finance lease assets

Assets recognized on the balance sheet for leases that transfer substantially all the risks and rewards of ownership. (Represents $491K in assets related to financed equipment.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Proto Labs has demonstrated solid revenue growth, with Q3 2025 revenue up 7.76% to $135.366 million and year-to-date revenue up 4.61% to $396.634 million. However, net income has seen a decline, with year-to-date net income down 10.32% to $15.242 million, indicating pressure on profitability. Operating expenses have also risen, contributing to this margin compression. The company's liquidity has improved, with cash and cash equivalents increasing to $104.422 million, and it continues to actively repurchase shares, reducing its outstanding share count.

Key Financial Figures

• $0.001 — ich registered Common Stock, Par Value $0.001 Per Share PRLB New York Stock Exchange

Filing Documents

• prlb-20250930.htm (10-Q) — 1182KB
• prlb-20250930xexx101.htm (EX-10.1) — 83KB
• prlb-2025930xexx311.htm (EX-31.1) — 10KB
• prlb-2025930xexx312.htm (EX-31.2) — 10KB
• prlb-2025930xexx321.htm (EX-32.1) — 7KB
• 0001443669-25-000013.txt ( ) — 6197KB
• prlb-20250930.xsd (EX-101.SCH) — 33KB
• prlb-20250930_cal.xml (EX-101.CAL) — 62KB
• prlb-20250930_def.xml (EX-101.DEF) — 146KB
• prlb-20250930_lab.xml (EX-101.LAB) — 525KB
• prlb-20250930_pre.xml (EX-101.PRE) — 354KB
• prlb-20250930_htm.xml (XML) — 932KB

Financial Statements

Financial Statements 2 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 28 4.

Controls and Procedures

Controls and Procedures 28 PART II 1.

Legal Proceedings

Legal Proceedings 29 1A.

Risk Factors

Risk Factors 29 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 3. Defaults Upon Senior Securities 29 4. Mine Safety Disclosures 30 5. Other Information 30 6. Exhibits 31 1 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Proto Labs, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (Unaudited) Assets Current assets Cash and cash equivalents $ 104,422 $ 89,071 Short-term marketable securities 14,817 14,019 Accounts receivable, net of allowance for doubtful accounts of $ 2,378 and $ 1,975 as of September 30, 2025, and December 31, 2024, respectively 77,790 66,504 Inventory 14,073 12,305 Income taxes receivable 4,681 2,906 Prepaid expenses and other current assets 10,009 10,049 Total current assets 225,792 194,854 Property and equipment, net 211,325 227,263 Goodwill 273,991 273,991 Other intangible assets, net 19,539 21,422 Long-term marketable securities 19,149 17,773 Operating lease assets 2,015 2,993 Finance lease assets 491 692 Other long-term assets 4,553 4,524 Total assets $ 756,855 $ 743,512 Liabilities and shareholders' equity Current liabilities Accounts payable $ 17,388 $ 15,504 Accrued compensation 23,268 16,550 Accrued liabilities and other 27,831 19,621 Current operating lease liabilities 890 1,287 Current finance lease liabilities 365 309 Total current liabilities 69,742 53,271 Long-term operating lease liabilities 1,188 1,633 Long-term finance lease liabilities — 287 Long-term deferred tax liabilities 16,038 13,565 Other long-term liabilities 5,168 4,605 Total liabilities 92,136 73,361 Shareholders' equity Preferred stock, $ 0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of each of September 30, 2025, and December 31, 2024 — — Common stock, $ 0.001 par value, authorized 150,000,000 shares; issued and outstanding 23,677,746 and 24,226,088 shares as of September 30, 2025, and December 31, 2024, respectively 23 24 Additional paid-in capital 450,852 453,705 Retained earnings 238,568 244,406 Accumulated other comprehensive loss ( 24,724 ) ( 27,984 ) Total shareholders' equity 664,719 670,151 T

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements Note 1 – Basis of Presentation The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X . In the opinion of management, the accompanying financial statements reflect all adjustments necessary for a fair presentation of the Company's statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (SEC) on February 21, 2025 . The accompanying Consolidated Balance Sheet as of December 31, 2024 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company's Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K filed on February 21, 2025 as referenced above. Note 2 – R

View Full Filing

View this 10-Q filing on SEC EDGAR